More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Dodds
H M
HM
Bishop
J F
JF
Rivory
L P
LP
D015746:Abdominal Pain / Q000139:chemically induced*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D012798:Sialorrhea / Q000139:chemically induced*
D000972:Antineoplastic Agents, Phytogenic; D002800:Cholinesterase Inhibitors; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D002166:Camptothecin